-
1
-
-
64949195390
-
Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development
-
B.D. Abbott Review of the expression of peroxisome proliferator-activated receptors alpha (PPAR alpha), beta (PPAR beta), and gamma (PPAR gamma) in rodent and human development Reprod. Toxicol. 27 2009 246 257
-
(2009)
Reprod. Toxicol.
, vol.27
, pp. 246-257
-
-
Abbott, B.D.1
-
2
-
-
67649980379
-
Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume
-
rd, T.E. Akiyama, C.H. Chang, L. Colwell, S. Debenham, T. Doebber, M. Einstein, K. Liu, M.E. McCann, D.E. Moller, E.S. Muise, Y. Tan, J.R. Thompson, K.K. Wong, M. Wu, L. Xu, P.T. Meinke, J.P. Berger, and H.B. Wood Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy) butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume J. Med. Chem. 52 2009 3846 3854
-
(2009)
J. Med. Chem.
, vol.52
, pp. 3846-3854
-
-
Acton, J.J.1
Akiyama, T.E.2
Chang, C.H.3
Colwell, L.4
Debenham, S.5
Doebber, T.6
Einstein, M.7
Liu, K.8
Mccann, M.E.9
Moller, D.E.10
Muise, E.S.11
Tan, Y.12
Thompson, J.R.13
Wong, K.K.14
Wu, M.15
Xu, L.16
Meinke, P.T.17
Berger, J.P.18
Wood, H.B.19
-
3
-
-
33750580948
-
Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity
-
T. Allen, F. Zhang, S.A. Moodie, L.E. Clemens, A. Smith, F. Gregoire, A. Bell, G.E. Muscat, and T.A. Gustafson Halofenate is a selective peroxisome proliferator-activated receptor gamma modulator with antidiabetic activity Diabetes 55 2006 2523 2533
-
(2006)
Diabetes
, vol.55
, pp. 2523-2533
-
-
Allen, T.1
Zhang, F.2
Moodie, S.A.3
Clemens, L.E.4
Smith, A.5
Gregoire, F.6
Bell, A.7
Muscat, G.E.8
Gustafson, T.A.9
-
4
-
-
84864976082
-
GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain
-
A.A. Amato, S. Rajagopalan, J.Z. Lin, B.M. Carvalho, A.C. Figueira, J. Lu, S.D. Ayers, M. Mottin, R.L. Silveira, P.C. Souza, R.H. Mourão, M.J. Saad, M. Togashi, L.A. Simeoni, D.S. Abdalla, M.S. Skaf, I. Polikparpov, M.C. Lima, S.L. Galdino, R.G. Brennan, J.D. Baxter, I.R. Pitta, P. Webb, K.J. Phillips, and F.A. Neves GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain J. Biol. Chem. 287 2012 28169 28179
-
(2012)
J. Biol. Chem.
, vol.287
, pp. 28169-28179
-
-
Amato, A.A.1
Rajagopalan, S.2
Lin, J.Z.3
Carvalho, B.M.4
Figueira, A.C.5
Lu, J.6
Ayers, S.D.7
Mottin, M.8
Silveira, R.L.9
Souza, P.C.10
Mourão, R.H.11
Saad, M.J.12
Togashi, M.13
Simeoni, L.A.14
Abdalla, D.S.15
Skaf, M.S.16
Polikparpov, I.17
Lima, M.C.18
Galdino, S.L.19
Brennan, R.G.20
Baxter, J.D.21
Pitta, I.R.22
Webb, P.23
Phillips, K.J.24
Neves, F.A.25
more..
-
5
-
-
84876421324
-
Polyacetylenes from Notopterygium incisum - New selective partial agonists of peroxisome proliferator-activated receptor-gamma
-
A.G. Atanasov, M. Blunder, N. Fakhrudin, X. Liu, S.M. Noha, C. Malainer, M.P. Kramer, A. Cocic, O. Kunert, A. Schinkovitz, E.H. Heiss, D. Schuster, V.M. Dirsch, and R. Bauer Polyacetylenes from Notopterygium incisum - new selective partial agonists of peroxisome proliferator-activated receptor-gamma PLoS One 8 2013 e61755
-
(2013)
PLoS One
, vol.8
-
-
Atanasov, A.G.1
Blunder, M.2
Fakhrudin, N.3
Liu, X.4
Noha, S.M.5
Malainer, C.6
Kramer, M.P.7
Cocic, A.8
Kunert, O.9
Schinkovitz, A.10
Heiss, E.H.11
Schuster, D.12
Dirsch, V.M.13
Bauer, R.14
-
6
-
-
84884684046
-
Honokiol: a non-adipogenic PPARγ agonist from nature
-
A.G. Atanasov, J.N. Wang, S.P. Gu, J. Bu, M.P. Kramer, L. Baumgartner, N. Fakhrudin, A. Ladurner, C. Malainer, A. Vuorinen, S.M. Noha, S. Schwaiger, J.M. Rollinger, D. Schuster, H. Stuppner, V.M. Dirsch, and E.H. Heiss Honokiol: a non-adipogenic PPARγ agonist from nature Biochim. Biophys. Acta 1830 2013 4813 4819
-
(2013)
Biochim. Biophys. Acta
, vol.1830
, pp. 4813-4819
-
-
Atanasov, A.G.1
Wang, J.N.2
Gu, S.P.3
Bu, J.4
Kramer, M.P.5
Baumgartner, L.6
Fakhrudin, N.7
Ladurner, A.8
Malainer, C.9
Vuorinen, A.10
Noha, S.M.11
Schwaiger, S.12
Rollinger, J.M.13
Schuster, D.14
Stuppner, H.15
Dirsch, V.M.16
Heiss, E.H.17
-
7
-
-
84862684037
-
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
-
L. Azoulay, H. Yin, K.B. Filion, J. Assayag, A. Majdan, M.N. Pollak, and S. Suissa The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study BMJ 344 2012 e3645
-
(2012)
BMJ
, vol.344
-
-
Azoulay, L.1
Yin, H.2
Filion, K.B.3
Assayag, J.4
Majdan, A.5
Pollak, M.N.6
Suissa, S.7
-
8
-
-
67349188030
-
Emerging role of PPAR ligands in the management of diabetic nephropathy
-
P. Balakumar, M.K. Arora, and M. Singh Emerging role of PPAR ligands in the management of diabetic nephropathy Pharmacol. Res. 60 2009 170 173
-
(2009)
Pharmacol. Res.
, vol.60
, pp. 170-173
-
-
Balakumar, P.1
Arora, M.K.2
Singh, M.3
-
9
-
-
84861740440
-
PPAR ligands and cardiovascular disorders: friend or foe
-
P. Balakumar, and G. Jagadeesh PPAR ligands and cardiovascular disorders: friend or foe Curr. Mol. Pharmacol. 5 2012 219 223
-
(2012)
Curr. Mol. Pharmacol.
, vol.5
, pp. 219-223
-
-
Balakumar, P.1
Jagadeesh, G.2
-
10
-
-
84863696819
-
Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders
-
P. Balakumar, and S. Kathuria Submaximal PPARγ activation and endothelial dysfunction: new perspectives for the management of cardiovascular disorders Br. J. Pharmacol. 166 2012 1981 1992
-
(2012)
Br. J. Pharmacol.
, vol.166
, pp. 1981-1992
-
-
Balakumar, P.1
Kathuria, S.2
-
11
-
-
83755220049
-
Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword?
-
P. Balakumar, and N. Mahadevan Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br. J. Pharmacol. 165 2012 373 379
-
(2012)
Br. J. Pharmacol.
, vol.165
, pp. 373-379
-
-
Balakumar, P.1
Mahadevan, N.2
-
12
-
-
34548182594
-
PPAR dual agonists: are they opening Pandor's Box?
-
P. Balakumar, M. Rose, S.S. Ganti, P. Krishan, and M. Singh PPAR dual agonists: are they opening Pandor's Box? Pharmacol. Res. 56 2007 91 98
-
(2007)
Pharmacol. Res.
, vol.56
, pp. 91-98
-
-
Balakumar, P.1
Rose, M.2
Ganti, S.S.3
Krishan, P.4
Singh, M.5
-
13
-
-
12444273748
-
Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator
-
J.P. Berger, A.E. Petro, K.L. Macnaul, L.J. Kelly, B.B. Zhang, K. Richards, A. Elbrecht, B.A. Johnson, G. Zhou, T.W. Doebber, C. Biswas, M. Parikh, N. Sharma, M.R. Tanen, G.M. Thompson, J. Ventre, A.D. Adams, R. Mosley, R.S. Surwit, and D.E. Moller Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator Mol. Endocrinol. 17 2003 662 676
-
(2003)
Mol. Endocrinol.
, vol.17
, pp. 662-676
-
-
Berger, J.P.1
Petro, A.E.2
Macnaul, K.L.3
Kelly, L.J.4
Zhang, B.B.5
Richards, K.6
Elbrecht, A.7
Johnson, B.A.8
Zhou, G.9
Doebber, T.W.10
Biswas, C.11
Parikh, M.12
Sharma, N.13
Tanen, M.R.14
Thompson, G.M.15
Ventre, J.16
Adams, A.D.17
Mosley, R.18
Surwit, R.S.19
Moller, D.E.20
more..
-
15
-
-
77955609161
-
Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD)
-
D. Bilik, L.N. McEwen, M.B. Brown, J.V. Selby, A.J. Karter, D.G. Marrero, V.C. Hsiao, C.W. Tseng, C.M. Mangione, N.L. Lasser, J.C. Crosson, and W.H. Herman Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD) Pharmacoepidemiol. Drug Saf. 19 2010 715 721
-
(2010)
Pharmacoepidemiol. Drug Saf.
, vol.19
, pp. 715-721
-
-
Bilik, D.1
Mcewen, L.N.2
Brown, M.B.3
Selby, J.V.4
Karter, A.J.5
Marrero, D.G.6
Hsiao, V.C.7
Tseng, C.W.8
Mangione, C.M.9
Lasser, N.L.10
Crosson, J.C.11
Herman, W.H.12
-
16
-
-
33846623798
-
Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets
-
J.D. Brown, and J. Plutzky Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets Circulation 115 2007 518 533
-
(2007)
Circulation
, vol.115
, pp. 518-533
-
-
Brown, J.D.1
Plutzky, J.2
-
17
-
-
33645394377
-
A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro
-
E. Burgermeister, A. Schnoebelen, A. Flament, J. Benz, M. Stihle, B. Gsell, A. Rufer, A. Ruf, B. Kuhn, H.P. Märki, J. Mizrahi, E. Sebokova, E. Niesor, and M. Meyer A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro Mol. Endocrinol. 20 2006 809 830
-
(2006)
Mol. Endocrinol.
, vol.20
, pp. 809-830
-
-
Burgermeister, E.1
Schnoebelen, A.2
Flament, A.3
Benz, J.4
Stihle, M.5
Gsell, B.6
Rufer, A.7
Ruf, A.8
Kuhn, B.9
Märki, H.P.10
Mizrahi, J.11
Sebokova, E.12
Niesor, E.13
Meyer, M.14
-
18
-
-
65649104489
-
MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation
-
A. Chandalia, H.J. Clarke, L.E. Clemens, B. Pandey, V. Vicena, P. Lee, B.E. Lavan, and F.M. Gregoire MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation PPAR Res. 2009 2009 706852
-
(2009)
PPAR Res.
, vol.2009
, pp. 706852
-
-
Chandalia, A.1
Clarke, H.J.2
Clemens, L.E.3
Pandey, B.4
Vicena, V.5
Lee, P.6
Lavan, B.E.7
Gregoire, F.M.8
-
19
-
-
84860838260
-
NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile
-
S. Chaudhary, A. Dube, V. Kothari, N. Sachan, and C.D. Upasani NS-1: a novel partial peroxisome proliferator-activated receptor γ agonist to improve insulin sensitivity and metabolic profile Eur. J. Pharmacol. 684 2012 154 160
-
(2012)
Eur. J. Pharmacol.
, vol.684
, pp. 154-160
-
-
Chaudhary, S.1
Dube, A.2
Kothari, V.3
Sachan, N.4
Upasani, C.D.5
-
20
-
-
33745495558
-
Can PPARgamma agonists have a role in the management of obesity-related hypertension?
-
V.T. Chetty, and A.M. Sharma Can PPARgamma agonists have a role in the management of obesity-related hypertension? Vasc. Pharmacol. 45 2006 46 53
-
(2006)
Vasc. Pharmacol.
, vol.45
, pp. 46-53
-
-
Chetty, V.T.1
Sharma, A.M.2
-
21
-
-
84879791655
-
Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system
-
M.C. Cho, D.H. Lee, E.J. Kim, J.Y. Lee, J.W. Kang, J.H. Song, Y. Chong, Y. Kim, J.T. Hong, and D.Y. Yoon Novel PPARγ partial agonists with weak activity and no cytotoxicity; identified by a simple PPARγ ligand screening system Mol. Cell. Biochem. 358 2011 75 83
-
(2011)
Mol. Cell. Biochem.
, vol.358
, pp. 75-83
-
-
Cho, M.C.1
Lee, D.H.2
Kim, E.J.3
Lee, J.Y.4
Kang, J.W.5
Song, J.H.6
Chong, Y.7
Kim, Y.8
Hong, J.T.9
Yoon, D.Y.10
-
22
-
-
84863718935
-
Bladder cancer: pioglitazone increases risk of bladder cancer
-
M. Clyne Bladder cancer: pioglitazone increases risk of bladder cancer Nat. Rev. Urol. 9 2012 353
-
(2012)
Nat. Rev. Urol.
, vol.9
, pp. 353
-
-
Clyne, M.1
-
23
-
-
84867571503
-
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs
-
H.M. Colhoun, S.J. Livingstone, H.C. Looker, A.D. Morris, S.H. Wild, R.S. Lindsay, C. Reed, P.T. Donnan, B. Guthrie, G.P. Leese, J. McKnight, D.W. Pearson, E. Pearson, J.R. Petrie, S. Philip, N. Sattar, F.M. Sullivan, P. McKeigue, and Scottish Diabetes Research Network Epidemiology Group Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs Diabetologia 55 2012 2929 2937
-
(2012)
Diabetologia
, vol.55
, pp. 2929-2937
-
-
Colhoun, H.M.1
Livingstone, S.J.2
Looker, H.C.3
Morris, A.D.4
Wild, S.H.5
Lindsay, R.S.6
Reed, C.7
Donnan, P.T.8
Guthrie, B.9
Leese, G.P.10
Mcknight, J.11
Pearson, D.W.12
Pearson, E.13
Petrie, J.R.14
Philip, S.15
Sattar, N.16
Sullivan, F.M.17
Mckeigue, P.18
Scottish Diabetes Research Network Epidemiology Group19
-
24
-
-
84874601304
-
Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor γ
-
J.C. de Groot, C. Weidner, J. Krausze, K. Kawamoto, F.C. Schroeder, S. Sauer, and K. Büssow Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor γ J. Med. Chem. 56 2013 1535 1543
-
(2013)
J. Med. Chem.
, vol.56
, pp. 1535-1543
-
-
De Groot, J.C.1
Weidner, C.2
Krausze, J.3
Kawamoto, K.4
Schroeder, F.C.5
Sauer, S.6
Büssow, K.7
-
25
-
-
82555175836
-
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data
-
A.M. Gallagher, L. Smeeth, S. Seabroke, H.G. Leufkens, and T.P. van Staa Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data PLoS One 6 2011 e28157
-
(2011)
PLoS One
, vol.6
-
-
Gallagher, A.M.1
Smeeth, L.2
Seabroke, S.3
Leufkens, H.G.4
Van Staa, T.P.5
-
26
-
-
67649598394
-
MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema
-
F.M. Gregoire, F. Zhang, H.J. Clarke, T.A. Gustafson, D.D. Sears, S. Favelyukis, J. Lenhard, D. Rentzeperis, L.E. Clemens, Y. Mu, and B.E. Lavan MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema Mol. Endocrinol. 23 2009 975 988
-
(2009)
Mol. Endocrinol.
, vol.23
, pp. 975-988
-
-
Gregoire, F.M.1
Zhang, F.2
Clarke, H.J.3
Gustafson, T.A.4
Sears, D.D.5
Favelyukis, S.6
Lenhard, J.7
Rentzeperis, D.8
Clemens, L.E.9
Mu, Y.10
Lavan, B.E.11
-
27
-
-
84898891705
-
Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis
-
S. He, Y.H. Tang, G. Zhao, X. Yang, D. Wang, and Y. Zhang Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis Tumour Biol. 35 2014 2095 2102
-
(2014)
Tumour Biol.
, vol.35
, pp. 2095-2102
-
-
He, S.1
Tang, Y.H.2
Zhao, G.3
Yang, X.4
Wang, D.5
Zhang, Y.6
-
28
-
-
67651121966
-
A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats
-
K. Henriksen, I. Byrjalsen, R.H. Nielsen, A.N. Madsen, L.K. Larsen, C. Christiansen, H. Beck-Nielsen, and M.A. Karsdal A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats Eur. J. Pharmacol. 616 2009 340 345
-
(2009)
Eur. J. Pharmacol.
, vol.616
, pp. 340-345
-
-
Henriksen, K.1
Byrjalsen, I.2
Nielsen, R.H.3
Madsen, A.N.4
Larsen, L.K.5
Christiansen, C.6
Beck-Nielsen, H.7
Karsdal, M.A.8
-
29
-
-
79955730238
-
Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy
-
K. Henriksen, I. Byrjalsen, P. Qvist, H. Beck-Nielsen, G. Hansen, B.J. Riis, H. Perrild, O.L. Svendsen, J. Gram, M.A. Karsdal, C. Christiansen, and BALLET Trial Investigators Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy Diabetes Metab. Res. Rev. 27 2011 392 401
-
(2011)
Diabetes Metab. Res. Rev.
, vol.27
, pp. 392-401
-
-
Henriksen, K.1
Byrjalsen, I.2
Qvist, P.3
Beck-Nielsen, H.4
Hansen, G.5
Riis, B.J.6
Perrild, H.7
Svendsen, O.L.8
Gram, J.9
Karsdal, M.A.10
Christiansen, C.11
Ballet Trial Investigators12
-
30
-
-
79953236112
-
Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials
-
A.V. Hernandez, A. Usmani, A. Rajamanickam, and A. Moheet Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials Am. J. Cardiovasc. Drugs 11 2011 115 128
-
(2011)
Am. J. Cardiovasc. Drugs
, vol.11
, pp. 115-128
-
-
Hernandez, A.V.1
Usmani, A.2
Rajamanickam, A.3
Moheet, A.4
-
31
-
-
67149146438
-
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
-
P.D. Home, S.J. Pocock, H. Beck-Nielsen, P.S. Curtis, R. Gomis, M. Hanefeld, N.P. Jones, M. Komajda, J.J. McMurray, and RECORD Study Team Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 2009 2125 2135
-
(2009)
Lancet
, vol.373
, pp. 2125-2135
-
-
Home, P.D.1
Pocock, S.J.2
Beck-Nielsen, H.3
Curtis, P.S.4
Gomis, R.5
Hanefeld, M.6
Jones, N.P.7
Komajda, M.8
Mcmurray, J.J.9
Record Study Team10
-
32
-
-
84925160303
-
-
accessed 04.10.14
-
http://www.diabetes.org.my/article.php?aid=837 (accessed 04.10.14.).
-
-
-
-
33
-
-
69749102008
-
Distal upper and lower limb fractures associated with thiazolidinedione use
-
S.G. Jones, S.R. Momin, M.W. Good, T.K. Shea, and K. Patric Distal upper and lower limb fractures associated with thiazolidinedione use Am. J. Manag. Care 15 2009 491 496
-
(2009)
Am. J. Manag. Care
, vol.15
, pp. 491-496
-
-
Jones, S.G.1
Momin, S.R.2
Good, M.W.3
Shea, T.K.4
Patric, K.5
-
34
-
-
69949096990
-
Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
-
D.N. Juurlink, T. Gomes, L.L. Lipscombe, P.C. Austin, J.E. Hux, and M.M. Mamdani Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study BMJ 339 2009 b2942
-
(2009)
BMJ
, vol.339
, pp. 2942
-
-
Juurlink, D.N.1
Gomes, T.2
Lipscombe, L.L.3
Austin, P.C.4
Hux, J.E.5
Mamdani, M.M.6
-
35
-
-
78651075521
-
PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects
-
M.K. Kim, Y.N. Chae, S.H. Choi, H.S. Moon, M.H. Son, M.H. Bae, H.H. Choi, Y. Hur, E. Kim, Y.H. Park, C.S. Park, J.G. Kim, J.I. Lim, and C.Y. Shin PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects Eur. J. Pharmacol. 650 2011 673 681
-
(2011)
Eur. J. Pharmacol.
, vol.650
, pp. 673-681
-
-
Kim, M.K.1
Chae, Y.N.2
Choi, S.H.3
Moon, H.S.4
Son, M.H.5
Bae, M.H.6
Choi, H.H.7
Hur, Y.8
Kim, E.9
Park, Y.H.10
Park, C.S.11
Kim, J.G.12
Lim, J.I.13
Shin, C.Y.14
-
36
-
-
63849177352
-
INT-131, a PPARgamma agonist for the treatment of type 2 diabetes
-
U. Kintscher, and M. Goebel INT-131, a PPARgamma agonist for the treatment of type 2 diabetes Curr. Opin. Investig. Drugs 10 2009 381 387
-
(2009)
Curr. Opin. Investig. Drugs
, vol.10
, pp. 381-387
-
-
Kintscher, U.1
Goebel, M.2
-
37
-
-
84900399238
-
KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes
-
V.R. Konda, A. Desai, G. Darland, N. Grayson, and J.S. Bland KDT501, a derivative from hops, normalizes glucose metabolism and body weight in rodent models of diabetes PLoS One 9 2014 e87848
-
(2014)
PLoS One
, vol.9
-
-
Konda, V.R.1
Desai, A.2
Darland, G.3
Grayson, N.4
Bland, J.S.5
-
38
-
-
84876591844
-
Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow
-
I. Kouskoumvekaki, R.K. Petersen, F. Fratev, O. Taboureau, T.E. Nielsen, T.I. Oprea, S.B. Sonne, E.N. Flindt, S.Ó. Jónsdóttir, and K. Kristiansen Discovery of a novel selective PPARγ ligand with partial agonist binding properties by integrated in silico/in vitro work flow J. Chem. Inf. Model. 53 2013 923 937
-
(2013)
J. Chem. Inf. Model.
, vol.53
, pp. 923-937
-
-
Kouskoumvekaki, I.1
Petersen, R.K.2
Fratev, F.3
Taboureau, O.4
Nielsen, T.E.5
Oprea, T.I.6
Sonne, S.B.7
Flindt, E.N.8
Jónsdóttir, S.Ó.9
Kristiansen, K.10
-
39
-
-
0033212964
-
PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance
-
N. Kubota, Y. Terauchi, H. Miki, H. Tamemoto, T. Yamauchi, K. Komeda, S. Satoh, R. Nakano, C. Ishii, T. Sugiyama, K. Eto, Y. Tsubamoto, A. Okuno, K. Murakami, H. Sekihara, G. Hasegawa, M. Naito, Y. Toyoshima, S. Tanaka, K. Shiota, T. Kitamura, T. Fujita, O. Ezaki, S. Aizawa, and T. Kadowaki PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance Mol. Cell 4 1999 597 609
-
(1999)
Mol. Cell
, vol.4
, pp. 597-609
-
-
Kubota, N.1
Terauchi, Y.2
Miki, H.3
Tamemoto, H.4
Yamauchi, T.5
Komeda, K.6
Satoh, S.7
Nakano, R.8
Ishii, C.9
Sugiyama, T.10
Eto, K.11
Tsubamoto, Y.12
Okuno, A.13
Murakami, K.14
Sekihara, H.15
Hasegawa, G.16
Naito, M.17
Toyoshima, Y.18
Tanaka, S.19
Shiota, K.20
Kitamura, T.21
Fujita, T.22
Ezaki, O.23
Aizawa, S.24
Kadowaki, T.25
more..
-
40
-
-
53049098128
-
Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone
-
P.J. Larsen, K. Lykkegaard, L.K. Larsen, J. Fleckner, P. Sauerberg, K. Wassermann, and E.M. Wulff Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone Eur. J. Pharmacol. 596 2008 173 179
-
(2008)
Eur. J. Pharmacol.
, vol.596
, pp. 173-179
-
-
Larsen, P.J.1
Lykkegaard, K.2
Larsen, L.K.3
Fleckner, J.4
Sauerberg, P.5
Wassermann, K.6
Wulff, E.M.7
-
41
-
-
84863154767
-
Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice
-
D.H. Lee, H. Huang, K. Choi, C. Mantzoros, and Y.B. Kim Selective PPARγ modulator INT131 normalizes insulin signaling defects and improves bone mass in diet-induced obese mice Am. J. Physiol. Endocrinol. Metab. 302 2012 E552 560
-
(2012)
Am. J. Physiol. Endocrinol. Metab.
, vol.302
, pp. E552-E560
-
-
Lee, D.H.1
Huang, H.2
Choi, K.3
Mantzoros, C.4
Kim, Y.B.5
-
42
-
-
79956217900
-
Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study
-
J.D. Lewis, A. Ferrara, T. Peng, M. Hedderson, W.B. Bilker, C.P. Quesenberry Jr., D.J. Vaughn, L. Nessel, J. Selby, and B.L. Strom Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
-
(2011)
Diabetes Care
, vol.34
, pp. 916-922
-
-
Lewis, J.D.1
Ferrara, A.2
Peng, T.3
Hedderson, M.4
Bilker, W.B.5
Quesenberry, Jr.C.P.6
Vaughn, D.J.7
Nessel, L.8
Selby, J.9
Strom, B.L.10
-
43
-
-
44049104049
-
T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties
-
Y. Li, Z. Wang, N. Furukawa, P. Escaron, J. Weiszmann, G. Lee, M. Lindstrom, J. Liu, X. Liu, H. Xu, O. Plotnikova, V. Prasad, N. Walker, R.M. Learned, and J.L. Chen T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties J. Biol. Chem. 283 2008 9168 9176
-
(2008)
J. Biol. Chem.
, vol.283
, pp. 9168-9176
-
-
Li, Y.1
Wang, Z.2
Furukawa, N.3
Escaron, P.4
Weiszmann, J.5
Lee, G.6
Lindstrom, M.7
Liu, J.8
Liu, X.9
Xu, H.10
Plotnikova, O.11
Prasad, V.12
Walker, N.13
Learned, R.M.14
Chen, J.L.15
-
44
-
-
77957223368
-
Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein
-
X. Liao, Y. Wang, and C.W. Wong Troglitazone induces cytotoxicity in part by promoting the degradation of peroxisome proliferator-activated receptor γ co-activator-1α protein Br. J. Pharmacol. 161 2010 771 781
-
(2010)
Br. J. Pharmacol.
, vol.161
, pp. 771-781
-
-
Liao, X.1
Wang, Y.2
Wong, C.W.3
-
45
-
-
79953203593
-
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
-
Y.K. Loke, C.S. Kwok, and S. Singh Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies BMJ 342 2011 d1309
-
(2011)
BMJ
, vol.342
, pp. 1309
-
-
Loke, Y.K.1
Kwok, C.S.2
Singh, S.3
-
46
-
-
84866707482
-
Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study
-
R. Mamtani, K. Haynes, W.B. Bilker, D.J. Vaughn, B.L. Strom, K. Glanz, and J.D. Lewis Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study J. Natl. Cancer Inst. 104 2012 1411 1421
-
(2012)
J. Natl. Cancer Inst.
, vol.104
, pp. 1411-1421
-
-
Mamtani, R.1
Haynes, K.2
Bilker, W.B.3
Vaughn, D.J.4
Strom, B.L.5
Glanz, K.6
Lewis, J.D.7
-
47
-
-
42949088130
-
Use of thiazolidinediones and fracture risk
-
C. Meier, M.E. Kraenzlin, M. Bodmer, S.S. Jick, H. Jick, and C.R. Meier Use of thiazolidinediones and fracture risk Arch. Intern. Med. 168 2008 820 825
-
(2008)
Arch. Intern. Med.
, vol.168
, pp. 820-825
-
-
Meier, C.1
Kraenzlin, M.E.2
Bodmer, M.3
Jick, S.S.4
Jick, H.5
Meier, C.R.6
-
48
-
-
84903893789
-
CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo
-
Y. Ming, X. Hu, Y. Song, Z.1. Liu, J. Li, R. Gao, Y. Zhang, H. Mei, T. Guo, L. Xiao, B. Wang, C. Wu, and X. Xiao CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo PLoS One 9 2014 e102102
-
(2014)
PLoS One
, vol.9
-
-
Ming, Y.1
Hu, X.2
Song, Y.3
Liu, Z.1.4
Li, J.5
Gao, R.6
Zhang, Y.7
Mei, H.8
Guo, T.9
Xiao, L.10
Wang, B.11
Wu, C.12
Xiao, X.13
-
49
-
-
60849095073
-
INT131: a selective modulator of PPAR gamma
-
A. Motani, Z. Wang, J. Weiszmann, L.R. McGee, G. Lee, Q. Liu, J. Staunton, Z. Fang, H. Fuentes, M. Lindstrom, J. Liu, D.H. Biermann, J. Jaen, N.P. Walker, R.M. Learned, J.L. Chen, and Y. Li INT131: a selective modulator of PPAR gamma J. Mol. Biol. 386 2009 1301 1311
-
(2009)
J. Mol. Biol.
, vol.386
, pp. 1301-1311
-
-
Motani, A.1
Wang, Z.2
Weiszmann, J.3
Mcgee, L.R.4
Lee, G.5
Liu, Q.6
Staunton, J.7
Fang, Z.8
Fuentes, H.9
Lindstrom, M.10
Liu, J.11
Biermann, D.H.12
Jaen, J.13
Walker, N.P.14
Learned, R.M.15
Chen, J.L.16
Li, Y.17
-
50
-
-
84866358522
-
Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study
-
A. Neumann, A. Weill, P. Ricordeau, J.P. Fagot, F. Alla, and H. Allemand Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study Diabetologia 55 2012 1953 1962
-
(2012)
Diabetologia
, vol.55
, pp. 1953-1962
-
-
Neumann, A.1
Weill, A.2
Ricordeau, P.3
Fagot, J.P.4
Alla, F.5
Allemand, H.6
-
51
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471
-
(2007)
N. Engl. J. Med.
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
52
-
-
77954136691
-
Bone loss and fracture risk associated with thiazolidinedione therapy
-
D.M. Riche, and S.T. King Bone loss and fracture risk associated with thiazolidinedione therapy Pharmacotherapy 30 2010 716 727
-
(2010)
Pharmacotherapy
, vol.30
, pp. 716-727
-
-
Riche, D.M.1
King, S.T.2
-
53
-
-
84896711938
-
Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use
-
V. Romero, C. Peyton, I. Gray, A. Hemal, and R. Terlecki Pathology of bladder cancer among diabetic patients undergoing radical cystectomy with a history of pioglitazone (Actos) use BMC Urol. 14 2014 10
-
(2014)
BMC Urol.
, vol.14
, pp. 10
-
-
Romero, V.1
Peyton, C.2
Gray, I.3
Hemal, A.4
Terlecki, R.5
-
54
-
-
33646099930
-
MBX-102: A novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes mellitus (T2DM) on concomitant insulin therapy [abstract 44-OR]
-
J. Rosenstock, F. Flores-Losano, S. Schwartz, G. Gonzalez-Galvez, and D.B. Karpf MBX-102: A novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes mellitus (T2DM) on concomitant insulin therapy [abstract 44-OR] Diabetes 54 2005 A11
-
(2005)
Diabetes
, vol.54
, pp. A11
-
-
Rosenstock, J.1
Flores-Losano, F.2
Schwartz, S.3
Gonzalez-Galvez, G.4
Karpf, D.B.5
-
55
-
-
77958529709
-
Cardiovascular risk and thiazolidinediones - What do meta-analyses really tell us?
-
G. Schernthaner, and R.J. Chilton Cardiovascular risk and thiazolidinediones - what do meta-analyses really tell us? Diabetes Obes. Metab. 12 2010 1023 1035
-
(2010)
Diabetes Obes. Metab.
, vol.12
, pp. 1023-1035
-
-
Schernthaner, G.1
Chilton, R.J.2
-
56
-
-
77954328462
-
Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone
-
S. Seto, K. Okada, K. Kiyota, S. Isogai, M. Iwago, T. Shinozaki, Y. Kitamura, Y. Kohno, and K. Murakami Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone J. Med. Chem. 53 2010 5012 5024
-
(2010)
J. Med. Chem.
, vol.53
, pp. 5012-5024
-
-
Seto, S.1
Okada, K.2
Kiyota, K.3
Isogai, S.4
Iwago, M.5
Shinozaki, T.6
Kitamura, Y.7
Kohno, Y.8
Murakami, K.9
-
57
-
-
34548580881
-
Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis
-
S. Singh, Y.K. Loke, and C.D. Furberg Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis JAMA 298 2007 1189 1195
-
(2007)
JAMA
, vol.298
, pp. 1189-1195
-
-
Singh, S.1
Loke, Y.K.2
Furberg, C.D.3
-
58
-
-
51349164431
-
Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events
-
C.I. Starner, J.A. Schafer, A.H. Heaton, and P.P. Gleason Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events J. Manag. Care Pharm. 14 2008 523 531
-
(2008)
J. Manag. Care Pharm.
, vol.14
, pp. 523-531
-
-
Starner, C.I.1
Schafer, J.A.2
Heaton, A.H.3
Gleason, P.P.4
-
59
-
-
84873285630
-
Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity
-
J.P. Taygerly, L.R. McGee, S.M. Rubenstein, J.B. Houze, T.D. Cushing, Y. Li, A. Motani, J.L. Chen, W. Frankmoelle, G. Ye, M.R. Learned, J. Jaen, S. Miao, P.B. Timmermans, M. Thoolen, P. Kearney, J. Flygare, H. Beckmann, J. Weiszmann, M. Lindstrom, N. Walker, J. Liu, D. Biermann, Z. Wang, A. Hagiwara, T. Iida, H. Aramaki, Y. Kitao, H. Shinkai, N. Furukawa, J. Nishiu, and M. Nakamura Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity Bioorg. Med. Chem. 21 2013 979 992
-
(2013)
Bioorg. Med. Chem.
, vol.21
, pp. 979-992
-
-
Taygerly, J.P.1
Mcgee, L.R.2
Rubenstein, S.M.3
Houze, J.B.4
Cushing, T.D.5
Li, Y.6
Motani, A.7
Chen, J.L.8
Frankmoelle, W.9
Ye, G.10
Learned, M.R.11
Jaen, J.12
Miao, S.13
Timmermans, P.B.14
Thoolen, M.15
Kearney, P.16
Flygare, J.17
Beckmann, H.18
Weiszmann, J.19
Lindstrom, M.20
Walker, N.21
Liu, J.22
Biermann, D.23
Wang, Z.24
Hagiwara, A.25
Iida, T.26
Aramaki, H.27
Kitao, Y.28
Shinkai, H.29
Furukawa, N.30
Nishiu, J.31
Nakamura, M.32
more..
-
60
-
-
83455210425
-
Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population
-
C.C. Wang, W.L. Chen, T.W. Kao, Y.W. Chang, C.H. Loh, and C.C. Chou Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population Clin. Ther. 33 2011 1904 1913
-
(2011)
Clin. Ther.
, vol.33
, pp. 1904-1913
-
-
Wang, C.C.1
Chen, W.L.2
Kao, T.W.3
Chang, Y.W.4
Loh, C.H.5
Chou, C.C.6
-
61
-
-
84908265684
-
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
-
L. Wang, B. Waltenberger, E.M. Pferschy-Wenzig, M. Blunder, X. Liu, C. Malainer, T. Blazevic, S. Schwaiger, J.M. Rollinger, E.H. Heiss, D. Schuster, B. Kopp, R. Bauer, H. Stuppner, V.M. Dirsch, and A.G. Atanasov Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review Biochem. Pharmacol. 92 2014 73 89
-
(2014)
Biochem. Pharmacol.
, vol.92
, pp. 73-89
-
-
Wang, L.1
Waltenberger, B.2
Pferschy-Wenzig, E.M.3
Blunder, M.4
Liu, X.5
Malainer, C.6
Blazevic, T.7
Schwaiger, S.8
Rollinger, J.M.9
Heiss, E.H.10
Schuster, D.11
Kopp, B.12
Bauer, R.13
Stuppner, H.14
Dirsch, V.M.15
Atanasov, A.G.16
-
62
-
-
74549202936
-
The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database
-
N. Ziyadeh, A.T. McAfee, C. Koro, J. Landon, and K. Arnold, Chan The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database Clin. Ther. 31 2009 2665 2677
-
(2009)
Clin. Ther.
, vol.31
, pp. 2665-2677
-
-
Ziyadeh, N.1
Mcafee, A.T.2
Koro, C.3
Landon, J.4
Arnold Chan, K.5
|